文献速递眼底病与葡萄膜炎

增生型糖尿病视网膜病变患者进展至平坦部玻璃体切除术

Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

该回顾性队列研究基于电子健康记录研究网络,纳入2023年1月至9月接受全视网膜光凝或抗血管内皮生长因子单药治疗的增生型糖尿病视网膜病变患者,经倾向评分匹配后比较平坦部玻璃体切除术、玻璃体出血及牵拉性视网膜脱离的发生率,发现全视网膜光凝单药治疗与更高的平坦部玻璃体切除术、玻璃体出血及牵拉性视网膜脱离发生率相关。

要点

  • 全视网膜光凝单药治疗与5年平坦部玻璃体切除术率较高相关(RR 1.18;95%CI 1.05-1.36;P<.001)。
  • 全视网膜光凝单药治疗与5年玻璃体出血率较高相关(RR 1.72;95%CI 1.52-1.95;P<.001)。
  • 全视网膜光凝单药治疗与5年牵拉性视网膜脱离率较高相关(RR 2.76;95%CI 2.26-3.37;P<.001)。

核心结论

  • 研究结果支持以下假设:与匹配的抗血管内皮生长因子单药治疗患者相比,接受全视网膜光凝单药治疗的增生型糖尿病视网膜病变患者更可能发生玻璃体出血、牵拉性视网膜脱离并接受平坦部玻璃体切除术。
  • 鉴于相对风险范围较宽,混杂因素可能解释了全视网膜光凝与抗血管内皮生长因子单药治疗同所评估结局之间部分关联。

研究设计与样本

  • 回顾性队列研究,使用聚合电子健康记录研究网络。
  • 纳入2023年1月至9月接受全视网膜光凝或抗血管内皮生长因子单药治疗的增生型糖尿病视网膜病变患者,行倾向评分匹配前共6020例。
  • 排除单药治疗后随访6个月或更短者,以及全视网膜光凝与抗血管内皮生长因子联合治疗者。
  • 数据分析于2023年9月进行。

主要发现

  • 全视网膜光凝队列平均(SD)年龄64.8(13.4)岁,6424例(50.88%)为女性,3562例(28.21%)为黑人、6180例(48.95%)为白人、2716例(21.51%)种族未知。
  • 抗血管内皮生长因子队列平均(SD)年龄66.1(13.2)岁,5399例(50.52%)为男性,2859例(26.75%)为黑人、5377例(50.31%)为白人、2382例(22.29%)种族未知。
  • 与抗血管内皮生长因子单药治疗患者相比,全视网膜光凝单药治疗与5年平坦部玻璃体切除术率较高相关(RR 1.18;95%CI 1.05-1.36;RD 1.37%;95%CI 0.39%-2.37%;P<.001),1年和3年时关联相似。
  • 全视网膜光凝单药治疗与5年玻璃体出血率较高相关(RR 1.72;95%CI 1.52-1.95;RD 7.05%;95%CI 5.41%-8.69%;P<.001)。
  • 全视网膜光凝单药治疗与5年牵拉性视网膜脱离率较高相关(RR 2.76;95%CI 2.26-3.37;RD 4.25%;95%CI 3.45%-5.05%;P<.001),6个月、1年和3年时关联幅度相似。

关键数值与推荐

  • 主要结局指标为平坦部玻璃体切除术、玻璃体出血或牵拉性视网膜脱离的发生率。
  • 暴露按新诊断增生型糖尿病视网膜病变患者接受全视网膜光凝或抗血管内皮生长因子药物单药治疗分层,使用现行操作术语代码确定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出鉴于相对风险范围较宽,混杂因素可能解释了全视网膜光凝与抗血管内皮生长因子单药治疗同所评估结局之间部分关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Diabetic Retinopathy Clinical Research Network Protocol S suggested that vitrectomy for vitreous hemorrhage (VH) or tractional retinal detachment (TRD) was more common among eyes assigned initially to panretinal photocoagulation (PRP) vs anti-vascular endothelial growth factor (anti-VEGF) for proliferative diabetic retinopathy (PDR). These clinical implications warrant further evaluation in the clinical practice setting. OBJECTIVE: To explore outcomes of PDR treated with PRP monotherapy compared with matched patients treated with anti-VEGF monotherapy. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using an aggregated electronic health records research network. Patients with PDR who received PRP or anti-VEGF monotherapy between January and September 2023 were included before propensity score matching. Patients were excluded with 6 or fewer months' follow-up after monotherapy or with a combination of PRP and anti-VEGF. Data were analyzed in September 2023. EXPOSURES: Patients with new PDR diagnoses stratified by monotherapy with PRP or anti-VEGF agents using Current Procedural Terminology code. MAIN OUTCOME MEASURES: Incidence of pars plana vitrectomy (PPV), VH, or TRD. RESULTS: Among 6020 patients (PRP cohort: mean [SD] age, 64.8 [13.4]; 6424 [50.88%] female; 3562 [28.21%] Black, 6180 [48.95%] White, and 2716 [21.51%] unknown race; anti-VEGF cohort: mean [SD] age, 66.1 [13.2]; 5399 [50.52%] male; 2859 [26.75%] Black, 5377 [50.31%] White, and 2382 [22.29%] unknown race) who received treatment, PRP monotherapy was associated with higher rates of PPV when compared with patients treated with anti-VEGF monotherapy at 5 years (RR, 1.18; 95% CI, 1.05-1.36; RD, 1.37%; 95% CI, 0.39%-2.37%; P < .001), with similar associations at 1 and 3 years. PRP monotherapy was associated with higher rates of VH at 5 years (relative risk [RR], 1.72; 95% CI, 1.52-1.95; risk difference [RD], 7.05; 95% CI, 5.41%-8.69%; P < .001) and higher rates of TRD at 5 years (RR, 2.76; 95% CI, 2.26-3.37; RD, 4.25%; 95% CI, 3.45%-5.05%; P < .001), with similar magnitudes of associations at 6 months, 1 year, and 3 years, when compared with patients treated with anti-VEGF monotherapy. CONCLUSIONS AND RELEVANCE: These findings support the hypothesis that patients with PDR treated with PRP monotherapy are more likely to develop VH, TRD, and undergo PPV when compared with matched patients treated with anti-VEGF monotherapy. However, given the wide range in relative risk, confounding factors may account for some of the association between PRP vs anti-VEGF monotherapy and outcomes evaluated.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Alsoudi AF, Wai KM, Koo E, et al. Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2024. PMID: 38842828. doi:10.1001/jamaophthalmol.2024.1844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。